What's new? Log in Free sign up

Bicara Therapeutics Inc. Common Stock (BCAX)

Company Profile

Company profile

Ticker

BCAX

Exchange

Website

CEO

Ms. Claire Mazumdar Clemon M.B.A., Ph.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

Former names

AccuStem Sciences Ltd

SEC CIK

Corporate docs

Underwriting Agreements

Plans of Reorganization

BCAX stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$41.00

Low target

$35.00

High target

$47.00

Latest filings (excl ownership)

View all

Quarterly report

Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Amendments to Articles of Incorporation or Bylaws

Registration of securities for employees

Prospectus supplement with pricing info

Notice of effectiveness

Registration of additional securities for an S-1

Certification of approval for exchange listing

IPO registration (amended)

11 Sep 24

Registration of securities on exchange

Latest ownership filings

View all

Invus Global Management, LLC

Red Tree GP, LLC

RA CAPITAL MANAGEMENT, L.P.

Peter Kolchinsky

DAVID BONDERMAN

Change in insider ownership

Change in insider ownership

Financial summary

Financial statements Chart BCAX financial data

Quarter (USD)	Sep 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
Cash on hand (at last report)			520.76 mm
Cash burn (monthly)			6.88 mm
Cash used (since last report)			19.19 mm
Cash remaining			501.57 mm
Runway (months of cash)			72.9

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2024

BCAX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0.00	0.00
Total shares	0.00	0.00
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

BCAX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
17 Sep 24	Flynn James E	Common Stock	Buy	Acquire P	Yes	No	18	35,000	630.00 k	897,587
17 Sep 24	Flynn James E	Common Stock	Buy	Acquire P	Yes	No	18	35,000	630.00 k	897,587
17 Sep 24	Flynn James E	Common Stock	Conversion	Acquire C	Yes	No	0	862,587	0.00	862,587
17 Sep 24	Flynn James E	Common Stock	Conversion	Acquire C	Yes	No	0	862,587	0.00	862,587
17 Sep 24	Flynn James E	Series C Preferred Stock Common Stock	Conversion	Dispose C	Yes	No	0	7,973,325	0.00	0
17 Sep 24	Flynn James E	Series C Preferred Stock Common Stock	Conversion	Dispose C	Yes	No	0	7,973,325	0.00	0
16 Sep 24	FMR	Common Stock	Conversion	Acquire C	Yes	No	0	392,085	0.00	1,115,333
16 Sep 24	FMR	Common Stock	Conversion	Acquire C	Yes	No	0	712,430	0.00	723,248
16 Sep 24	FMR	Common Stock	Conversion	Acquire C	Yes	No	0	10,818	0.00	10,818
16 Sep 24	FMR	Series C Preferred Stock Common Stock	Conversion	Dispose C	Yes	No	0	392,085	0.00	0

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session

HC Wainwright & Co. Initiates Coverage On Bicara Therapeutics with Buy Rating, Announces Price Target of $42

HC Wainwright & Co. analyst Robert Burns initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Buy rating and announces Price Target of $42.

Bicara Therapeutics Q3 2024 GAAP EPS $(1.60) Misses $(0.44) Estimate

Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(1.60) per share which missed the analyst consensus estimate of $(0.44) by 263.64 percent.

Cantor Fitzgerald Initiates Coverage On Bicara Therapeutics with Overweight Rating

This Wells Fargo Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Press releases

From Benzinga Pro

Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

On track to initiate FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Completed upsized initial public offering, raising approximately $362 million in gross proceeds, with full exercise of the

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference

BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors,

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.